Larvol Delta - Biotheryx-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Trial-of-BTX9341-a-FirstinClass-Dual-Bifunctional-Degrader-of-CDK46-as-a-Monotherapy-and-in-Combination-with-Fulvestrant-for-HRHER2-Breast-Cancer

BTX-9341 - BioTheryX

https://www.prnewswire.com/news-releases/biotheryx-announces-first-patient-dosed-in-phase-1-clinical-trial-of-btx-9341-a-first-in-class-dual-bifunctional-degrader-of-cdk46-as-a-monotherapy-and-in-combination-with-fulvestrant-for-hrher2--breast-cancer-302198738.html

Jul 17, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next